Arbutus Biopharma CorporationABUSNASDAQ
LOADING
|||
Switch Symbol:
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -71.25% | -26.62% | +15.14% | +522.19% | -60.49% |
| Gross Profit Growth | -71.25% | +0.00% | -569.65% | +522.19% | -61.31% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +12.83% | +10.20% | +8.59% | +1.87% | +1.47% |
| Weighted Average Shares Diluted Growth | +12.83% | +12.78% | +8.59% | +2.32% | +1.47% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -25.93% | +35.64% | -44.74% | -50.41% | -43.72% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -11.47% | -8.79% | -22.14% | -35.48% | -30.43% |
| Book Value per Share Growth | -20.61% | -16.66% | -36.41% | -33.48% | -28.64% |
| Debt Growth | -32.52% | -85.22% | -85.28% | -85.39% | -86.36% |
| R&D Expense Growth | -29.23% | -49.84% | -41.84% | -64.65% | -59.52% |
| SG&A Expenses Growth | -22.34% | +65.30% | +9.79% | -55.90% | -33.15% |